Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
e non » _ non (Expand Search), a non (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
e non » _ non (Expand Search), a non (Expand Search)
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
ngLVA degradation kinetics.
Published 2022“…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”
-
76
-
77
-
78
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
-
79
-
80
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”